ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Trends Analyst Outlook Journalist POV

59 hedge funds and large institutions have $67.4M invested in Arbutus Biopharma in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

more capital invested

Capital invested by funds: $ → $

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

more ownership

Funds ownership: →

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

Holders
59
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$501K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$10.3M
2
+$6.06M
3
+$5.27M
4
CAC
Cowen and Company
New York
+$2.58M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$797K

Top Sellers

1
-$9.57M
2
-$1.59M
3
-$806K
4
SFM
Sphera Funds Management
Israel
-$763K
5
Renaissance Technologies
Renaissance Technologies
New York
-$257K
Name Holding Trade Value Shares
Change 		Change in
Stake
51
$1K
52
$1K
53
$195
54
–
55
–
56
–
57
–
58
–
59
–
60
–
61
–
62
–
63
–
1 2
3